Logo image of JRJC

CHINA FINANCE ONLINE CO-ADR (JRJC) Stock Fundamental Analysis

NASDAQ:JRJC - Nasdaq - ADR

3.99  -2.45 (-38.04%)

After market: 4.15 +0.16 (+4.01%)

Fundamental Rating

1

Overall JRJC gets a fundamental rating of 1 out of 10. We evaluated JRJC against 225 industry peers in the Capital Markets industry. JRJC has a bad profitability rating. Also its financial health evaluation is rather negative. JRJC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year JRJC has reported negative net income.
JRJC Yearly Net Income VS EBIT VS OCF VS FCFJRJC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 20M -20M

1.2 Ratios

Industry RankSector Rank
ROA -14.95%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JRJC Yearly ROA, ROE, ROICJRJC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 20 -20 -40 -60 -80 -100

1.3 Margins

Industry RankSector Rank
OM -28%
PM (TTM) -26.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JRJC Yearly Profit, Operating, Gross MarginsJRJC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

JRJC has about the same amout of shares outstanding than it did 1 year ago.
JRJC has a worse debt/assets ratio than last year.
JRJC Yearly Shares OutstandingJRJC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 50K 100K 150K 200K
JRJC Yearly Total Debt VS Total AssetsJRJC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 50M 100M 150M

2.2 Solvency

JRJC has an Altman-Z score of 6.09. This indicates that JRJC is financially healthy and has little risk of bankruptcy at the moment.
JRJC has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 6.09
ROIC/WACCN/A
WACCN/A
JRJC Yearly LT Debt VS Equity VS FCFJRJC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 20M -20M 40M 60M 80M

2.3 Liquidity

JRJC has a Current Ratio of 0.91. This is a bad value and indicates that JRJC is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.91 indicates that JRJC may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.91
Quick Ratio 0.91
JRJC Yearly Current Assets VS Current LiabilitesJRJC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 50M 100M

More info and screens

1

3. Growth

3.1 Past

JRJC shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.52%.
JRJC shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -67.27% yearly.
JRJC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 12.68%.
Measured over the past years, JRJC shows a very negative growth in Revenue. The Revenue has been decreasing by -17.92% on average per year.
EPS 1Y (TTM)6.52%
EPS 3Y-67.27%
EPS 5YN/A
EPS Q2Q%-238.92%
Revenue 1Y (TTM)12.68%
Revenue growth 3Y-2.08%
Revenue growth 5Y-17.92%
Sales Q2Q%51.89%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JRJC Yearly Revenue VS EstimatesJRJC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 20M 40M 60M 80M 100M
JRJC Yearly EPS VS EstimatesJRJC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JRJC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JRJC Price Earnings VS Forward Price EarningsJRJC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -0.54
JRJC Per share dataJRJC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JRJC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA FINANCE ONLINE CO-ADR

NASDAQ:JRJC (1/20/2022, 8:18:38 PM)

After market: 4.15 +0.16 (+4.01%)

3.99

-2.45 (-38.04%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0.51%
Inst Owner Change-90.42%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.74M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B 0.93
P/tB N/A
EV/EBITDA -0.54
EPS(TTM)-4.6
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS16.38
BVpS4.31
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.95%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -28%
PM (TTM) -26.5%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.91
Quick Ratio 0.91
Altman-Z 6.09
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.52%
EPS 3Y-67.27%
EPS 5YN/A
EPS Q2Q%-238.92%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.68%
Revenue growth 3Y-2.08%
Revenue growth 5Y-17.92%
Sales Q2Q%51.89%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A